- Home
- ATAI vs ARCT Comparison
ATAI vs ARCT Comparison
Compare ATAI & ARCT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ATAI
- ARCT
- Stock Information
- Founded
- ATAI 2018
- ARCT 2013
- Country
- ATAI Germany
- ARCT United States
- Employees
- ATAI N/A
- ARCT N/A
- Industry
- ATAI Biotechnology: Pharmaceutical Preparations
- ARCT Biotechnology: Pharmaceutical Preparations
- Sector
- ATAI Health Care
- ARCT Health Care
- Exchange
- ATAI Nasdaq
- ARCT Nasdaq
- Market Cap
- ATAI 282.6M
- ARCT 298.3M
- IPO Year
- ATAI 2021
- ARCT N/A
- Fundamental
- Price
- ATAI $2.49
- ARCT $12.81
- Analyst Decision
- ATAI Strong Buy
- ARCT Strong Buy
- Analyst Count
- ATAI 3
- ARCT 8
- Target Price
- ATAI $10.50
- ARCT $52.33
- AVG Volume (30 Days)
- ATAI 2.4M
- ARCT 464.1K
- Earning Date
- ATAI 05-14-2025
- ARCT 05-12-2025
- Dividend Yield
- ATAI N/A
- ARCT N/A
- EPS Growth
- ATAI N/A
- ARCT N/A
- EPS
- ATAI N/A
- ARCT N/A
- Revenue
- ATAI $1,863,000.00
- ARCT $143,680,000.00
- Revenue This Year
- ATAI $242.21
- ARCT N/A
- Revenue Next Year
- ATAI N/A
- ARCT $42.36
- P/E Ratio
- ATAI N/A
- ARCT N/A
- Revenue Growth
- ATAI 572.56
- ARCT 15.38
- 52 Week Low
- ATAI $1.03
- ARCT $8.04
- 52 Week High
- ATAI $2.64
- ARCT $45.00
- Technical
- Relative Strength Index (RSI)
- ATAI 80.34
- ARCT 56.34
- Support Level
- ATAI $2.18
- ARCT $11.51
- Resistance Level
- ATAI $2.38
- ARCT $13.00
- Average True Range (ATR)
- ATAI 0.20
- ARCT 1.01
- MACD
- ATAI 0.07
- ARCT 0.09
- Stochastic Oscillator
- ATAI 88.14
- ARCT 66.07
About ATAI ATAI Life Sciences N.V.
ATAI Life Sciences NV is a clinical-stage biopharmaceutical company on a mission to develop effective mental health treatments to transform patient outcomes. The company's pipeline of psychedelic-based therapies includes VLS-01 (buccal film DMT) for treatment-resistant depression (TRD) and EMP-01 (oral R-MDMA) for social anxiety disorder. It is also advancing a drug discovery program to identify novel, non-hallucinogenic 5-HT2AR agonists for TRD.
About ARCT Arcturus Therapeutics Holdings Inc.
Arcturus Therapeutics Holdings Inc is an RNA medicines company focused on opportunities in rare diseases with a current focus on liver and respiratory diseases. It operates in one business segment, which includes all activities related to the discovery, development and commercialization of messenger RNA medicines. The company's pipeline includes LUNAR-OTC, LUNAR-CF, LUNAR-FLU, and LUNAR-COV19.